Prognostic factors for overall survival of patients with head and neck soft tissue sarcoma based on 25 years data from the Netherlands Cancer registry. This is an ASCO Meeting Abstract from the 2016 ...
A phase I study of the BCR-ABL tyrosine kinase inhibitor nilotinib and cetuximab in patients with solid tumors that can be treated with cetuximab. Background: In 2004, FDA declared the abandon rate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback